THE GLYCEMIC IMPACT OF SYZYGIUM CERASOIDEUM IN DIABETIC RATS

This study aimed to evaluate the glycemic impact of Syzygium cerasoideum in normal as well as streptozotocin (STZ) induced diabetic rat model. The glycemic impact of CESC & MESC extracts were evaluated 4h post-administration in normoglycemic rats, and STZ induced diabetic animals over a period of 21 days. Variation of administered doses of CESC and MESC extracts of Syzygium cerasoideum impacted the blood glucose level (mg/dl) of normoglycemic rodents with observable hypoglycemic effects at 2h. Glibenclamide (600µg/kg) showed 32.56% lowering of blood glucose level, while CESC showed 29.33% lowering at a dose of 400mg/kg, and 25.61% lowering was observed in case of 200mg/kg administered dose of MESC. STZ-induced diabetic animals treated with 200mg/kg, 400mg/kg of both extracts demonstrated noteworthy decrease of blood glucose levels during a treatment span of day 21(CESC200mg/kg:45.56%, CESC400mg/kg: 41.25%, MESC200mg/kg: 46.22%, MESC400mg/kg: 43.24%, respectively).Maximum reduction in blood glucose was observed in CESC and MESC extract dosage of 400mg/kg. However, commercially available, and clinically approved glibenclamide lowered blood glucose by 63.66%. After treatment with the extracts the liver enzyme were diminished in the diabetic rats in comparision to untreated diabetic rats. Untreated diabetic mice exhibited reduced activity of antioxidant enzymes. The level of antioxidant enzymes were normalized in the test animals after treatment with CESC and MESC, with levels at par with glibenclamide treated rats. The diabetic treated experimental group demonstrated a increase in body weight in comparison to the diabetic control group. Combinatorial administration of both extracts at 200mg/kg, 400mg/kg dosages caused critical increment in glycogen level within the liver. Conclusion: Our results show the potential application of CESC and MESC extracts of Syzygium cerasoideum as antidiabetic agents.